Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Prognosis of treatment response (pathological complete response) in breast cancer.

Nikas JB, Low WC, Burgio PA.

Biomark Insights. 2012;7:59-70. doi: 10.4137/BMI.S9387. Epub 2012 May 8.


Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer.

Nikas JB, Boylan KL, Skubitz AP, Low WC.

Cancer Inform. 2011;10:233-47. doi: 10.4137/CIN.S8104. Epub 2011 Oct 3.


Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.


Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.

Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.

Cancer. 2011 Aug 15;117(16):3682-90. doi: 10.1002/cncr.25953. Epub 2011 Feb 8.


Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.

Cameron DA, Gregory WM, Bowman A, Anderson ED, Levack P, Forouhi P, Leonard RC.

Br J Cancer. 2000 Jul;83(1):98-103.


Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer.

Sota Y, Naoi Y, Tsunashima R, Kagara N, Shimazu K, Maruyama N, Shimomura A, Shimoda M, Kishi K, Baba Y, Kim SJ, Noguchi S.

Ann Oncol. 2014 Jan;25(1):100-6. doi: 10.1093/annonc/mdt427.


An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.

Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A.

PLoS One. 2008 Apr 2;3(4):e1908. doi: 10.1371/journal.pone.0001908. Retraction in: PLoS One. 2011;6(9). doi: 10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4.


Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.


Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.

Breast Cancer Res. 2006;8(3):R31. Epub 2006 Jun 21.


Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L.

Clin Cancer Res. 2010 Nov 1;16(21):5351-61. doi: 10.1158/1078-0432.CCR-10-1265. Epub 2010 Sep 9.


Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.

Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A.

Breast Cancer Res. 2001;3(3):183-91. Epub 2001 Feb 1.


The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.


Breast cancer and neoadjuvant therapy: any predictive marker?

Vyzula R, Dusek L, Zaloudík J, Demlová R, Klimes D, Selvekerová S.

Neoplasma. 2004;51(6):471-80.


Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J.

Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5.


The use of mammography in breast preservation in locally advanced breast cancer.

Pierce L, Adler D, Helvie M, Lichter A, Merajver S.

Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):571-7.


Supplemental Content

Support Center